Morgan Stanley lowered the firm’s price target on Amicus to $18 from $19 and keeps an Overweight rating on the shares. The firm’s estimates are in line with consensus on Galafold revenues and Pombiliti plus Opfolda revenues, the analyst tells investors in a preview note. The firm will be looking out for updates on the Pombiliti plus Opfolda launch and whether the company is tracking to full-year non-GAAP profitability, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD: